
  
    
      
        
        Accurate_NNP staging_NN of_IN cancers_NNS is_VBZ one_CD of_IN the_DT most_RBS important_JJ parts_NNS of_IN the_DT work_NN up_RB of_IN
        patients_NNS for_IN both_DT prediction_NN of_IN prognosis_NN and_CC determination_NN of_IN the_DT most_RBS appropriate_JJ
        treatment_NN ._. And_CC an_DT essential_JJ part_NN of_IN this_DT work_NN up_RB is_VBZ assessing_VBG whether_IN or_CC not_RB there_EX has_VBZ been_VBN
        lymphatic_JJ spread_NN ._. Current_JJ methods_NNS include_VBP surgical_JJ removal_NN of_IN nodes_NNS for_IN examination_NN and_CC
        various_JJ types_NNS of_IN imaging_NN ,_, ranging_VBG from_IN ultrasound_NN to_TO newer_JJR technologies_NNS such_JJ as_IN magnetic_JJ
        resonance_NN imaging_NN (_( MRI_NNP )_) ._. All_DT these_DT methods_NNS have_VBP problems_NNS ;_: some_DT are_VBP very_RB invasive_JJ ,_, others_NNS
        are_VBP very_RB time_NN consuming_NN ,_, and_CC none_NN are_VBP completely_RB reliable_JJ ._.
        However_RB in_IN one_CD of_IN the_DT more_RBR exciting_JJ crossovers_NNS from_IN chemistry_NN into_IN medicine_NN ,_, researchers_NNS
        have_VBP developed_VBN nanoparticles_NNS to_TO improve_VB the_DT diagnostic_JJ accuracy_NN of_IN MRI_NNP ._. The_DT nanoparticles_NNS
        contain_VBP a_DT central_JJ superparamagnetic_JJ iron_NN oxide_NN core_NN and_CC are_VBP covered_VBN by_IN dextran_NN ,_, imparting_VBG
        long_JJ circulation_NN times_NNS and_CC biocompatibility_NN ._. When_WRB injected_VBN intravenously_RB ,_, the_DT nanoparticles_NNS
        localize_NN to_TO lymphoid_NN tissue_NN ,_, and_CC are_VBP internalized_JJ into_IN macrophages_NNS ._. There_EX is_VBZ then_RB a_DT
        decrease_NN in_IN signal_NN intensity_NN on_IN T_NN 2_CD -_: and_CC T_NN 2_CD *_NN -_: weighted_JJ images_NNS ,_, and_CC when_WRB metastases_NNS are_VBP
        present_JJ there_EX is_VBZ a_DT recognizably_RB abnormal_JJ pattern_NN on_IN MRI_NNP scans_VBZ ._.
        In_IN a_DT previous_JJ paper_NN published_VBN in_IN the_DT 
        New_NNP England_NNP Journal_NNP of_IN Medicine_NNP ,_, Ralph_NNP Weissleder_NNP and_CC colleagues_NNS
        described_VBD using_VBG these_DT nanoparticles_NNS to_TO assess_VB lymphoid_NN spread_VBD in_IN patients_NNS with_IN prostate_NN
        cancer_NN ._. Now_RB ,_, in_IN a_DT paper_NN published_VBN in_IN this_DT month_NN 's_POS 
        PLoS_NNP Medicine_NNP ,_, they_PRP have_VBP gone_VBN further_RB by_IN extending_VBG the_DT analysis_NN to_TO
        patients_NNS with_IN different_JJ types_NNS of_IN cancer_NN ,_, and_CC producing_VBG an_DT algorithm_NN that_WDT allows_VBZ
        semiautomation_NN of_IN the_DT procedure_NN ._.
        The_DT authors_NNS developed_VBD the_DT algorithm_NN in_IN a_DT training_NN group_NN of_IN 36_CD patients_NNS and_CC then_RB
        validated_JJ it_PRP in_IN a_DT group_NN of_IN 34_CD patients_NNS ._. The_DT results_NNS are_VBP encouraging_VBG :_: the_DT analysis_NN showed_VBD a_DT
        sensitivity_NN of_IN 98_CD %_NN (_( 95_CD %_NN confidence_NN interval_NN ,_, 88_CD %_NN –_NN 99_CD %_NN )_) and_CC a_DT specificity_NN of_IN 92_CD %_NN (_( 95_CD %_NN
        confidence_NN interval_NN ,_, 87_CD %_NN –_NN 96_CD %_NN )_) ._. The_DT advantages_NNS of_IN automating_VBG this_DT procedure_NN are_VBP substantial_JJ ,_,
        not_RB least_JJS because_IN it_PRP can_MD remove_VB the_DT problem_NN of_IN different_JJ observers_NNS assessing_VBG data_NNS
        differently_RB ._.
        And_CC what_WP is_VBZ more_JJR ,_, once_RB the_DT data_NNS have_VBP been_VBN collected_VBN and_CC assessed_VBD it_PRP is_VBZ possible_JJ to_TO
        reconstruct_VB a_DT virtual_JJ picture_NN of_IN the_DT patient_NN 's_POS lymph_NN nodes_NNS ,_, thus_RB potentially_RB allowing_VBG
        accurate_JJ surgical_JJ removal_NN of_IN the_DT nodes_NNS ._.
      
    
  
